S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study
Purpose This prospective study in a real-world setting investigated the feasibility and safety of S-1 plus nimotuzumab (S-1-Nimo) based concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients who failed to neoadjuvant chemotherapy or chemoimmunot...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2024.2417464 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850247992994430976 |
|---|---|
| author | Xin Wang Guojie Feng Xiongtao Yang Nuo Yu Ziyu Zheng Jiao Li Xiaozheng Kang Xiankai Chen Ruixiang Zhang Yong Li Zhen Wang Lei Deng Tao Zhang Wenyang Liu Jianyang Wang Wenqing Wang Qinfu Feng Zefen Xiao Zongmei Zhou Nan Bi Yin Li Jianjun Qin |
| author_facet | Xin Wang Guojie Feng Xiongtao Yang Nuo Yu Ziyu Zheng Jiao Li Xiaozheng Kang Xiankai Chen Ruixiang Zhang Yong Li Zhen Wang Lei Deng Tao Zhang Wenyang Liu Jianyang Wang Wenqing Wang Qinfu Feng Zefen Xiao Zongmei Zhou Nan Bi Yin Li Jianjun Qin |
| author_sort | Xin Wang |
| collection | DOAJ |
| description | Purpose This prospective study in a real-world setting investigated the feasibility and safety of S-1 plus nimotuzumab (S-1-Nimo) based concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients who failed to neoadjuvant chemotherapy or chemoimmunotherapy.Methods LA-ESCC patients who failed to converse to resectable disease after neoadjuvant chemotherapy or chemoimmunotherapy were enrolled to receive the 4-week S-1-Nimo regimen of radiotherapy (40 Gy in 20 fractions, 5 days per week), S-1 chemotherapy, and nimotuzumab. Then, after surgical assessments, patients evaluated as resectable disease received surgery; patients with unresectable disease continued to receive definitive radiotherapy (50–60 Gy in 25–30 fractions, 5 days per week) concurrently with S-1-Nimo. The primary endpoint was event-free survival (EFS).Results Sixty-four patients were enrolled and evaluated. The median follow-up time was 23.2 months. Median EFS was 9.6 (95% confidence interval [CI], 7.1–14.0) months, with an estimated 2-year EFS rate of 24.2%. The median overall survival (OS) and the estimated OS rate at 2 years were 13.4 (95% CI, 10.3–17.5) months and 31.2%, respectively. Twelve underwent surgery, with a surgical conversion rate of 18.8% and an R0 resection rate of 100.0%. Subgroup analysis identified the significantly prolonged EFS and OS in patients who experienced radical surgery (median EFS, not reached vs. 8.7 months; p = .0117. median OS, 24.9 vs. 10.6 months; p = .0205) as compared to those treated with CCRT. Of 64 patients, grade 3 adverse events mainly included radiation esophagitis (4.7%), anemia (1.6%), and thrombocytopenia (1.6%).Conclusion The study demonstrated the reasonable efficacy and promising safety of the S-1-Nimo-based CCRT in LA-ESCC patients with failure to neoadjuvant chemotherapy or chemoimmunotherapy. |
| format | Article |
| id | doaj-art-abb9729164b44daf94e9a10e4b455026 |
| institution | OA Journals |
| issn | 1538-4047 1555-8576 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Cancer Biology & Therapy |
| spelling | doaj-art-abb9729164b44daf94e9a10e4b4550262025-08-20T01:58:48ZengTaylor & Francis GroupCancer Biology & Therapy1538-40471555-85762024-12-0125110.1080/15384047.2024.2417464S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective studyXin Wang0Guojie Feng1Xiongtao Yang2Nuo Yu3Ziyu Zheng4Jiao Li5Xiaozheng Kang6Xiankai Chen7Ruixiang Zhang8Yong Li9Zhen Wang10Lei Deng11Tao Zhang12Wenyang Liu13Jianyang Wang14Wenqing Wang15Qinfu Feng16Zefen Xiao17Zongmei Zhou18Nan Bi19Yin Li20Jianjun Qin21Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Beijing Changping Hospital, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, ChinaPurpose This prospective study in a real-world setting investigated the feasibility and safety of S-1 plus nimotuzumab (S-1-Nimo) based concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients who failed to neoadjuvant chemotherapy or chemoimmunotherapy.Methods LA-ESCC patients who failed to converse to resectable disease after neoadjuvant chemotherapy or chemoimmunotherapy were enrolled to receive the 4-week S-1-Nimo regimen of radiotherapy (40 Gy in 20 fractions, 5 days per week), S-1 chemotherapy, and nimotuzumab. Then, after surgical assessments, patients evaluated as resectable disease received surgery; patients with unresectable disease continued to receive definitive radiotherapy (50–60 Gy in 25–30 fractions, 5 days per week) concurrently with S-1-Nimo. The primary endpoint was event-free survival (EFS).Results Sixty-four patients were enrolled and evaluated. The median follow-up time was 23.2 months. Median EFS was 9.6 (95% confidence interval [CI], 7.1–14.0) months, with an estimated 2-year EFS rate of 24.2%. The median overall survival (OS) and the estimated OS rate at 2 years were 13.4 (95% CI, 10.3–17.5) months and 31.2%, respectively. Twelve underwent surgery, with a surgical conversion rate of 18.8% and an R0 resection rate of 100.0%. Subgroup analysis identified the significantly prolonged EFS and OS in patients who experienced radical surgery (median EFS, not reached vs. 8.7 months; p = .0117. median OS, 24.9 vs. 10.6 months; p = .0205) as compared to those treated with CCRT. Of 64 patients, grade 3 adverse events mainly included radiation esophagitis (4.7%), anemia (1.6%), and thrombocytopenia (1.6%).Conclusion The study demonstrated the reasonable efficacy and promising safety of the S-1-Nimo-based CCRT in LA-ESCC patients with failure to neoadjuvant chemotherapy or chemoimmunotherapy.https://www.tandfonline.com/doi/10.1080/15384047.2024.2417464Concurrent chemoradiotherapyS-1nimotuzumablocally advanced ESCCreal-world studychemoimmunotherapy |
| spellingShingle | Xin Wang Guojie Feng Xiongtao Yang Nuo Yu Ziyu Zheng Jiao Li Xiaozheng Kang Xiankai Chen Ruixiang Zhang Yong Li Zhen Wang Lei Deng Tao Zhang Wenyang Liu Jianyang Wang Wenqing Wang Qinfu Feng Zefen Xiao Zongmei Zhou Nan Bi Yin Li Jianjun Qin S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study Cancer Biology & Therapy Concurrent chemoradiotherapy S-1 nimotuzumab locally advanced ESCC real-world study chemoimmunotherapy |
| title | S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study |
| title_full | S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study |
| title_fullStr | S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study |
| title_full_unstemmed | S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study |
| title_short | S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study |
| title_sort | s 1 based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy a real world prospective study |
| topic | Concurrent chemoradiotherapy S-1 nimotuzumab locally advanced ESCC real-world study chemoimmunotherapy |
| url | https://www.tandfonline.com/doi/10.1080/15384047.2024.2417464 |
| work_keys_str_mv | AT xinwang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT guojiefeng s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT xiongtaoyang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT nuoyu s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT ziyuzheng s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT jiaoli s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT xiaozhengkang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT xiankaichen s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT ruixiangzhang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT yongli s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT zhenwang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT leideng s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT taozhang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT wenyangliu s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT jianyangwang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT wenqingwang s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT qinfufeng s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT zefenxiao s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT zongmeizhou s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT nanbi s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT yinli s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy AT jianjunqin s1basedconcurrentchemoradiotherapyplusnimotuzumabinpatientswithlocallyadvancedesophagealsquamouscellcarcinomawhofailedneoadjuvanttherapyarealworldprospectivestudy |